Enbrel(R) (etanercept) Data to be Presented at the 2009 American College of Rheumatology Scientif...(impacted by government investigations li...),Health

Date:10/16/2009

impacted by government investigations, litigation and products liability claims. We depend on third parties for a significant portion of our manufacturing capacity for the supply of certain of our current and future products and limits on supply may constrain sales of certain of our current products and product candidate development.

In addition, sales of our products are affected by the reimbursement policies imposed by third-party payors, including governments, private insurance plans and managed care providers and may be affected by regulatory, clinical and guideline developments and domestic and international trends toward managed care and health care cost containment as well as U.S. legislation affecting pharmaceutical pricing and reimbursement. Government and others' regulations and reimbursement policies may affect the development, usage and pricing of our products. In addition, we compete with other companies with respect to some of our marketed products as well as for the discovery and development of new products. We believe that some of our newer products, product candidates or new indications for existing products, may face competition when and as they are approved and marketed. Our products may compete against products that have lower prices, established reimbursement, superior performance, are easier to administer, or that are otherwise competitive with our products. In addition, while we routinely obtain patents for our products and technology, the protection offered by our patents and patent applications may be challenged, invalidated or circumvented by our competitors and there can be no guarantee of our ability to obtain or maintain patent protection for our products or product candidates. We cannot guarantee that we will be able to produce commercially successful products or maintain the commercial success of our existing products. Our stock price may be affected by actual or perceived market opportunity, competitive position, and succ
'/>"/>

SOURCE Amgen Copyright©2009 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4 5 6 7 8 9
Related medicine news :

1. Enbrel(R) (etanercept) Is the First Biologic With Published Efficacy and Safety Data for up to a Decade of Continuous Use for the Treatment of Moderate to Severe Rheumatoid Arthritis
2. Plastic Surgery 2009 News Briefs - Selected Research to be Presented on Tuesday, October 27
3. Plastic Surgery 2009 News Briefs - Selected Research to be Presented on Monday, October 26
4. Plastic Surgery 2009 News Briefs - Select Research to be Presented on Sunday, October 25
5. Plastic Surgery 2009 News Briefs -- Research To Be Presented on Saturday, October 24
6. Novel Information about Vulnerable Coronary Artery Plaque to be Presented at Transcatheter Cardiovascular Therapeutics (TCT) 2009
7. PolyOne Presented with Frost & Sullivan Medical Product Award
8. CRF announces featured clinical trials to be presented at TCT 2009 in San Francisco
9. Kuvan and Naglazyme Data to Be Presented at the 11th Annual ICIEM Meeting
10. Centers of Excellence Awards Presented to Over 100 Nursing Facilities as Nursing Facilities Reach the Tipping Point in Treating Pressure Ulcers
11. CRF announces late breaking trials to be presented at TCT 2009 in San Francisco